Compare ICMB & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | PLUR |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 33.9M |
| IPO Year | 2013 | 2001 |
| Metric | ICMB | PLUR |
|---|---|---|
| Price | $1.88 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 55.9K | 5.4K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 27.66% | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | $4.75 | $293.97 |
| P/E Ratio | $47.00 | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $1.60 | $2.82 |
| 52 Week High | $3.28 | $7.13 |
| Indicator | ICMB | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 27.26 | 48.34 |
| Support Level | N/A | $3.19 |
| Resistance Level | $3.00 | $3.42 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 26.09 | 42.43 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.